Hard to compare them. they are in very different stage. QCOR's main drug has already been in the mkt place. it has a very low PE because there is mkt fears drug is not going to sell as well. VRTX is valued today for the potential of its yet to be approved drug. VRTX has revenue but wont have net income for a few years. I find drug companies in two buckets. those that have potential block buster drugs in the pipeline and those that already have them in the market and have real earnings. Those stocks in the first bucket will have tremendous rise and falls as we saw in the rise of VRTX and THRX. Those in the second bucket will have less spectacular rise and falls but still can be very profitable. The biggest drug companies are in the second bucket.